30th Sep 2020 21:37
Sensyne Health PLC - clinical artificial intelligence technology company with headquarters in Oxford - To collaborate with Oxford University under which Sensyne will provide software for remote data collection for the AVID-CC phase 2 clinical trial of the anti-TNF drug adalimumab to prevent respiratory failure due to Covid-19. Trial's purpose is to assess effectiveness of drug in preventing progression to respiratory failure or death due to infection.
Current stock price: 58.00 pence
Year-to-date change: down 16%
By Dayo Laniyan; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
SENS.L